OriGene Technologies

Moving from Genomics to Proteomics

BioCat's longstanding valued partner OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches.

OriGene's vision is to prepare comprehensive, genome-wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research.

OriGene Technologies uses high-throughput, genome-wide approaches to develop products for pharmaceutical, biotechnology, and academic research. Their flagship products are over 40,000 human full-length TrueClone cDNA and over 35,000 human TrueORF cDNA clones.

Based on the TrueORF cDNA clones, OriGene has developed a broad offering of full-length human proteins, such as “MVPro” proteins, expressed in mammalian cells, ideal for functional studies.

In 2010, OriGene initiated the TrueMAB project to develop mouse monoclonal antibodies against protein antigens with the goal to develop protein assays for every human protein. Furthermore the company also began the TrueRAB project to develop a single B cell cloning technology for the generation of recombinant rabbit monoclonal antibodies with high affinity and against targets with low immunogenicity in the mouse system.

The current OriGene product portfolio has over a million products that enable scientists analyze the proteome universe. It includes four key brands: MVPro, TrueRAB, TrueMAB and ultra-specific antibodies UltraMAB. Researchers can start their journey with a clone from the TrueClone collection and complete the analysis by developing an assay system using ultra-specific antibodies. OriGene empowers researchers in their journey to move from genomics to proteomics.